• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Bacopa monnieri

Neuroprotective effects of Bacopa monnieri in Parkinson’s disease model

December 13, 2019

https://link.springer.com/article/10.1007%2Fs11011-019-00526-w

https://www.ncbi.nlm.nih.gov/pubmed/31834548?dopt=Abstract

TITLE:
Neuroprotective effects of Bacopa monnieri in Parkinson’s disease model.

DESCRIPTION:
Neuroprotective effects of Bacopa monnieri in Parkinson’s disease model.

Metab Brain Dis. 2019 Dec 13;:

Authors: Singh B, Pandey S, Rumman M, Mahdi AA

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra region and the presence of α-synuclein aggregates in the striatum and surrounding areas of brain. Evidences suggest that neuroinflammation plays a role in the progression of PD. We examined the neuro-protective effects of Bacopa monnieri (BM) in regulating neuroinflammation. Administration of BM suppressed the level of pro-inflammatory cytokines, decreased the levels of α-synuclein, and reduced reactive oxygen species (ROS) generation in PD animal model. Pre-treatment of BM showed more prominent results as compare to co- and post-treatment. Results suggest that Bacopa can limit inflammation in the different areas of brain, thus, offers a promising source of novel therapeutics for the treatment of many CNS disorders.

PMID: 31834548 [PubMed – as supplied by publisher]

PMID:
PubMed:31834548

DATE FOUND:
12/14/19 06:02AM

LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31834548?dopt=Abstract

Powered by Urgent Research

Copyright © 2025 Urgent Research